1-7 of 7
E. Gabriela Chiorean
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

E. Gabriela Chiorean, Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia Jalikis, Michael J. Pishvaian, Jordan Berlin, Marcus S. Noel, Jennifer M. Suga, Ignacio Garrido-Laguna, Dana Backlund Cardin, Marc R. Radke, Mai Duong, Shay Bellasea, Andrew M. Lowy, Howard S. Hochster
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6314–6322.
https://doi.org/10.1158/1078-0432.CCR-21-1789
Published: 01 December 2021
View article titled, Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513
Open the PDF for Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513 in another window
Includes: Supplementary data
Journal Articles

Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Katelyn T. Byrne, Courtney B. Betts, Rosemarie Mick, Shamilene Sivagnanam, David L. Bajor, Daniel A. Laheru, E. Gabriela Chiorean, Mark H. O'Hara, Shannon M. Liudahl, Craig Newcomb, Cécile Alanio, Ana P. Ferreira, Byung S. Park, Takuya Ohtani, Austin P. Huffman, Sara A. Väyrynen, Andressa Dias Costa, Judith C. Kaiser, Andreanne M. Lacroix, Colleen Redlinger, Martin Stern, Jonathan A. Nowak, E. John Wherry, Martin A. Cheever, Brian M. Wolpin, Emma E. Furth, Elizabeth M. Jaffee, Lisa M. Coussens, Robert H. Vonderheide
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4574–4586.
https://doi.org/10.1158/1078-0432.CCR-21-1047
Published: 15 August 2021
View article titled, Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
Open the PDF for Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Zev A. Wainberg, Howard S. Hochster, Edward J. Kim, Ben George, Aparna Kaylan, E. Gabriela Chiorean, David M. Waterhouse, Martin Guiterrez, Aparna Parikh, Rishi Jain, Daniel Ricardo Carrizosa, Hatem H. Soliman, Thomas Lila, David J. Reiss, Daniel W. Pierce, Rafia Bhore, Sibabrata Banerjee, Larry Lyons, Chrystal U. Louis, Teng Jin Ong, Peter J. O'Dwyer
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (18): 4814–4822.
https://doi.org/10.1158/1078-0432.CCR-20-0099
Published: 15 September 2020
View article titled, Open-label, Phase I Study of Nivolumab Combined with <em>nab</em>-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
Open the PDF for Open-label, Phase I Study of Nivolumab Combined with <em>nab</em>-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer

Michael S. Gordon, Francisco Robert, Daniela Matei, David S. Mendelson, Jonathan W. Goldman, E. Gabriela Chiorean, Robert M. Strother, Ben K. Seon, William D. Figg, Cody J. Peer, Delia Alvarez, Bonne J. Adams, Charles P. Theuer, Lee S. Rosen
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (23): 5918–5926.
https://doi.org/10.1158/1078-0432.CCR-14-1143
Published: 30 November 2014
View article titled, An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer
Open the PDF for An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer in another window
Journal Articles

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Gregory L. Beatty, Drew A. Torigian, E. Gabriela Chiorean, Babak Saboury, Alex Brothers, Abass Alavi, Andrea B. Troxel, Weijing Sun, Ursina R. Teitelbaum, Robert H. Vonderheide, Peter J. O'Dwyer
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (22): 6286–6295.
https://doi.org/10.1158/1078-0432.CCR-13-1320
Published: 14 November 2013
View article titled, A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Open the PDF for A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

Glen J. Weiss, Jeffrey R. Infante, E. Gabriela Chiorean, Mitesh J. Borad, Johanna C. Bendell, Julian R. Molina, Raoul Tibes, Ramesh K. Ramanathan, Karen Lewandowski, Suzanne F. Jones, Mario E. Lacouture, Virginia K. Langmuir, Hank Lee, Stew Kroll, Howard A. Burris, III
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (9): 2997–3004.
https://doi.org/10.1158/1078-0432.CCR-10-3425
Published: 01 May 2011
View article titled, Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies
Open the PDF for Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies in another window
Includes: Supplementary data
Journal Articles

A Phase I and Pharmacokinetic Trial of Erlotinib in Combination with Weekly Docetaxel in Patients with Taxane-Naive Malignancies

E. Gabriela Chiorean, Jennifer M. Porter, Anne E. Foster, Amal S.H. Al Omari, Christy A. Yoder, Karen L. Fife, R. Matthew Strother, Daryl J. Murry, Menggang Yu, David R. Jones, Christopher J. Sweeney
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (4): 1131–1137.
https://doi.org/10.1158/1078-0432.CCR-07-0437
Published: 15 February 2008
View article titled, A Phase I and Pharmacokinetic Trial of Erlotinib in Combination with Weekly Docetaxel in Patients with Taxane-Naive Malignancies
Open the PDF for A Phase I and Pharmacokinetic Trial of Erlotinib in Combination with Weekly Docetaxel in Patients with Taxane-Naive Malignancies in another window